News

Introducing our team of bloggers for 2018 

Roche’s ocrelizumab receives licence in the EU for relapsing forms of multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS)

With the turn of the New Year MS & Me is expanding and diversifying. In this post, we also say ‘goodbye’ to a number of friends

Calling all cyclists

More than 9,000 people are living with Multiple Sclerosis in Ireland. Multiple Sclerosis (MS), meaning ‘many scars’, is the most common disabling neurological disease affecting young adults in Ireland. MS impacts the motor, sensory and cognitive functioning of the body and is usually diagnosed between 20 and 40 years of age. 

'Quiet Time' 

Irish life sciences company, Genomics Medicine Ireland (GMI) have announced an important scientific research study aimed at unlocking the mystery of the genetic and lifestyle factors that contribute to MS. Volunteers with MS currently being treated at St. Vincent’s University Hospital, Tallaght Hospital, Cork University Hospital or Altnagelvin Hospital in Derry are invited to participate in the study which aims to identify these factors in order to find better treatments, diagnoses and, ultimately, a cure for MS. GMI also hopes to rollout additional study sites around the country in future.  

Yesterday the HSE published their Service Plan for 2018. The plan is available here. 

This week from the MS & Me blog archive Emma Rogan shares her thoughts on minding your energy levels, minding your mind and making it the Best Christmas, EVER! 

MS Ireland's response to the announcement of funding for respite care by Minister for Health Simon Harris